The mastermind approach to CNS drug therapy: translational prediction of human brain distribution, target site kinetics, and therapeutic effects.
about
Deriving therapies for children with primary CNS tumors using pharmacokinetic modeling and simulation of cerebral microdialysis dataEffect of intranasal stem cell administration on the nigrostriatal system in a mouse model of Parkinson's diseaseMonitoring vigabatrin in head injury patients by cerebral microdialysis: obtaining pharmacokinetic measurements in a neurocritical care setting.Prediction of brain clozapine and norclozapine concentrations in humans from a scaled pharmacokinetic model for rat brain and plasma pharmacokineticsEmerging Insights for Translational Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Studies: Towards Prediction of Nose-to-Brain Transport in HumansElucidating the Aβ42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer's Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical DataTreating disorders of the neonatal central nervous system: pharmacokinetic and pharmacodynamic considerations with a focus on antiepileptics.Intracerebral Distribution of the Oncometabolite d-2-Hydroxyglutarate in Mice Bearing Mutant Isocitrate Dehydrogenase Brain Tumors: Implications for Tumorigenesis.Utility of CSF in translational neuroscience.Translational aspects of blood-brain barrier transport and central nervous system effects of drugs: from discovery to patients.Transporters as Drug Targets in Neurological DiseasesA Generic Multi-Compartmental CNS Distribution Model Structure for 9 Drugs Allows Prediction of Human Brain Target Site ConcentrationsExamining the Uptake of Central Nervous System Drugs and Candidates across the Blood-Brain Barrier.News from the editors of Fluids and Barriers of the CNS.Diurnal variation in P-glycoprotein-mediated transport and cerebrospinal fluid turnover in the brain.The impact of P-gp functionality on non-steady state relationships between CSF and brain extracellular fluid.Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastoma.Novel CNS drug discovery and development approach: model-based integration to predict neuro-pharmacokinetics and pharmacodynamics.Quantitative and Mechanistic Understanding of AZD1775 Penetration across Human Blood-Brain Barrier in Glioblastoma Patients Using an IVIVE-PBPK Modeling Approach.Nano-ropinirole for the management of Parkinsonism: blood-brain pharmacokinetics and carrier localization.Development of a Rat Plasma and Brain Extracellular Fluid Pharmacokinetic Model for Bupropion and Hydroxybupropion Based on Microdialysis Sampling, and Application to Predict Human Brain Concentrations.Access to the CNS: Biomarker Strategies for Dopaminergic Treatments.Rasagiline-encapsulated chitosan-coated PLGA nanoparticles targeted to the brain in the treatment of parkinson's disease
P2860
Q30700231-66F5B704-5F22-4975-BECF-93693A49E44CQ33597885-CB1E1AB9-CFB2-4FDE-B60D-5BDE4E8EA11AQ34570859-AB1A17C9-C359-48F3-86EB-56F54F6DB859Q34667775-BE93B347-8BEE-419E-B88E-E9376F00403EQ35529165-E9930B7B-0406-4DC1-88DD-1842CC6AF728Q36354749-6A9E6241-D25D-45C7-968D-ED9DDA905EF9Q36410220-8664DD75-528B-4F0E-A2B7-949FDDB0F4B5Q37326123-11618DD6-1D4D-4CBC-949B-7DC37B9DF0F6Q38080762-265C83B0-3931-4677-B6B5-4886830CD4BBQ38351399-14B9AC9A-8441-4D9C-9BC4-D72FC653FEC9Q38905608-0488D7D3-EE86-4C56-8D69-87A1EE7A2425Q39172795-D35C6F11-F411-4590-8A87-2E03310155CFQ39754769-568B4803-2700-4B7A-BCD5-957D52F718CCQ40797762-09E457E3-3743-4853-88E2-B8B654065950Q42091226-049B6400-B138-48C4-8B66-273C9963BC32Q43069428-FDD9CFBE-3786-40E8-BC45-D98392B3425FQ47894479-F4DE605B-DF01-418A-B3CB-42E972551C87Q47949927-704CC45E-8B76-4313-9286-56601A6852CFQ48105538-D0265D42-5678-4F3A-BC0E-F72AE282293FQ48187795-05EE3A05-8EAE-4A00-838C-53D452148B86Q48877772-4E8594DD-119F-4A54-B28A-F70DF68D61CDQ49949879-8E0AAF6A-4BAB-475E-925E-4553829C6A4EQ57369531-36F8801F-B3F2-4B14-A2DE-3EED699E3B8A
P2860
The mastermind approach to CNS drug therapy: translational prediction of human brain distribution, target site kinetics, and therapeutic effects.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
The mastermind approach to CNS ...... tics, and therapeutic effects.
@ast
The mastermind approach to CNS ...... tics, and therapeutic effects.
@en
type
label
The mastermind approach to CNS ...... tics, and therapeutic effects.
@ast
The mastermind approach to CNS ...... tics, and therapeutic effects.
@en
prefLabel
The mastermind approach to CNS ...... tics, and therapeutic effects.
@ast
The mastermind approach to CNS ...... tics, and therapeutic effects.
@en
P2860
P356
P1476
The mastermind approach to CNS ...... tics, and therapeutic effects.
@en
P2093
Elizabeth Cm de Lange
P2860
P2888
P356
10.1186/2045-8118-10-12
P577
2013-02-22T00:00:00Z
P5875
P6179
1029286707